Combination antiretroviral therapy (ART) has dramatically reduced the morbidity and mortality associated with HIV infection.1 However, current combination therapies have a high rate of failure due to issues involving potency, toxicity, patient adherence, individual pharmacokinetics, and/or viral resistance.2 Regardless of the cause for failure, emergence of viral resistance to one or more of the antiretroviral agents being taken is a frequent outcome. The anticipated pattern of nucleoside reverse transcription inhibitor (NRTI) resistance in the average subject failing first- or second-line ART therapy is the M184V mutation plus 1-2 thymidine analogue-associated mutations (TAMs).3
Cross-resistance among NRTIs is an important consideration in the selection of subsequent regimens. Among the most important mutations to consider are the 6 major TAMs (D67N, K70R, T215Y/F, M41L, L210W, and K219Q/E), as well as the K65R, L74V, and M184V mutations.4 The multinucleoside-resistant complexes marked by the Q151M or T69S mutations may abolish most of the antiviral activity of the NRTIclass.5,6 Mutations selected by zidovudine (ZDV) or stavudine (d4T) can have a negative effect on the susceptibility of virus to all the NRTIs in vitro, but both abacavir (ABC) and tenofovir (TDF) have been shown to confer clinical benefit in subjects with virus harboring some of these mutations.7-9 The K65R mutation decreases susceptibility to ABC, didanosine (ddI), and TDF.10,11 The L74V mutation decreases susceptibility to ddI and ABC while increasing susceptibility to ZDV and possibly TDF.12-14 Lamivudine (3TC) rapidly selects for the M184V mutation upon virologic rebound, leading to a large increase in phenotypic resistance to 3TC.15 However, HIV-1 with the M184V mutation has a reduced replication rate compared with the wild type, and reverse transcription with this mutation exhibits enzymatic defects such as reduced pyrophosphorolysis and decreased processivity.16 The mutation reverses the effect of the TAMs in vitro and can also delay the emergence of these mutations.15 Additionally, although the M184V mutation is associated with a small (2- to 3-fold) reduction in susceptibility to ABC,17,18 it enhances susceptibility to TDF, d4T, and ZDV.19
There is currently limited clinical data to address the use of ABC and 3TC as part of combination therapy in ART-experienced subjects. Therapy becomes more individualized in later lines of therapy based upon a subject's treatment history and/or viral genotype, which may require regimens with a higher degree of potency sufficient to achieve viral control. The sustained benefit of 3TC in the presence of the M184V mutation, such as the antagonistic effect of M184V on TAMs, the increased susceptibility of M184 virus to ZDV, d4T, and TDF, and the antiviral efficacy of ABC in subjects with M184V virus, provides a rationale for including 3TC, ABC, and TDF in subsequent treatment regimens after virologic failure (VF) with the M184V mutation.
CAL30001 compared two 4-drug regimens containing ABC, once daily (QD) or twice daily (BID), in combination with 3TC, TDF, and either a protease inhibitor (PI) or a nonnucleoside reverse transcription inhibitor (NNRTI) based upon past treatment history. The ABC QD arm received ABC + 3TC as a fixed-dose combination (FDC) tablet. The target population was likely to have a dominant plasma virus carrying some mutations that may have altered virologic susceptibility to the NRTIs proposed but was not expected to abolish clinically significant antiviral activity of the antiretroviral agents tested in this trial. The noninferiority of the QD dosing of ABC was tested relative to BID dosing, in the setting of a 4-drug regimen for VF.
Male or nonpregnant female out-patients were eligible for study enrollment if they were ≥18 years; had HIV infection, as documented by HIV-1 antibody ELISA and confirmed by Western blot test; were ART experienced and receiving a stable drug regimen containing 3 NRTIs, or 2 NRTIs plus 1 PI or NNRTI for at least 3 months, but naive to TDF; had plasma HIV-1 RNA levels ≥1000 copies/mL and CD4 cell counts >50 cells/μL at least once within 21 days of study entry; and harbored no more than 3 NRTI-related mutations, with no K65R, L74V, 69S insertion, or Q151M mutations by genotyping of subjects plasma from screening.
Study Design and Treatment Regimens
This 48-week trial was a Phase 3, randomized, open-label, parallel-group study conducted at 57 centers in Europe and North America. The primary efficacy outcome was to test the noninferiority of ABC in an FDC tablet administered QD versus ABC administered BID with 3TC QD as separate entities (SE), as measured by plasma HIV-1 RNA average area under the curve minus baseline (AAUCMB) over 48 weeks. Eligible subjects were stratified according to study entry plasma HIV-1 RNA level (<5000 vs. ≥5000 copies/mL) and viral genotype (presence vs. absence of the M184V/I mutation).
After a 21-day screening phase, subjects were randomized (1:1) to 1 of 2 treatment groups:
FDC arm: ABC/3TC FDC QD + TDF QD + new NNRTI or PI;
SE arm: ABC BID + 3TC QD + TDF QD + new NNRTI or PI.
The ABC/3TC combination was administered as a single FDC tablet containing 600 mg of ABC (GlaxoSmithKline, Research Triangle Park, NC) and 300 mg of 3TC (GlaxoSmithKline), or as one 300-mg tablet of ABC BID and two 150-mg tablets of 3TC QD. TDF was administered as a single 300-mg tablet of TDF (Gilead Sciences, Foster City, CA). All background PIs and NNRTIs were initiated along with the above study drugs and were supplied to patients as prescribed medications by their doctor.
Study Assessment and Monitoring
Patients enrolled in the study were evaluated at baseline; weeks 2, 4, 8, and 12; and every 12 weeks thereafter through week 48. Interim history was obtained, targeted physical examinations were performed, and a Centers for Diseases Control and Prevention Classification20 was established at screening visit. Hematology and serum chemistry were assessed at all visits. An assessment of adverse events (AEs) was performed at all visits and evaluated using the Division of AIDS table for grading the severity of adult adverse experiences.21 Samples for the plasma HIV-1 RNA levels and CD4 cell counts were assessed at all scheduled visits. Subject assessments were conducted at all study visits, regardless of study treatment received, including switches, until last subject completed 48 weeks of treatment or permanently discontinued from study.
Quantitative plasma HIV-1 RNA levels were measured using the Roche COBAS Amplicor HIV-1 Monitor Test version 1.5 using Standard and/or UltraSensitive polymerase chain reaction (PCR) methods (lower limit of quantitation, 400 and 50 copies/mL, respectively; Roche Diagnostics, Basel, Switzerland). VF was confirmed if the plasma HIV-1 RNA did not achieve <400 copies/mL by week 24 while on study medication, or if the plasma HIV-1 RNA levels were ≥400 copies/mL on at least 2 consecutive occasions while on study medication following complete virologic response during the treatment phase (at least 2 previous occasions while on study medication where plasma HIV-1 RNA was <400 copies/mL). CD4 cell counts were measured by flow cytometry. Plasma samples were collected by the investigator or appropriate designated study personnel at screening for genotyping. Additional storage plasma samples for exploratory genotypic and phenotypic evaluations were also collected at screening and subsequent study visits. All viral evaluations of genotype and phenotype were performed by ViroLogic Inc. (South San Francisco, CA) according to their standard procedures.
Adherence to the ABC + 3TC (FDC or SE) and TDF components of the regimen were evaluated using pill counts of unused medication. Pill counts were performed each time the subject received a refill supply of the medication and upon discontinuation of a medication.
A total of 186 subjects with a 1:1 randomization stratified by screening plasma HIV-1 RNA and genotype would provide 90% power to assess the noninferiority of the FDC arm compared with the SE arm at the 0.05 level of significance. Eligible subjects were randomized and stratified using permuted blocks within each stratum. The primary efficacy analysis of plasma HIV-1 RNA AAUCMB was based on the "intention-to-treat (ITT)-exposed, switch-included" population. This was defined as all subjects randomized and exposed to at least 1 dose of any study drugs. For the analyses of plasma HIV-1 RNA and CD4 cell count profiles, the switch-included strategy was applied to this population (ITT-exposed population, switch included, also referred to as "observed data"). As such, treatment changes that may have occurred during the treatment phase of this study were included in the analyses.
The 2 treatment groups were compared by the two-sided 95% confidence interval (CI) at week 48. Noninferiority was established when the 95% CI was entirely to the left of 0.4 log10 HIV-1 RNA copies/mL.22,23 Antiviral efficacy was also measured by a comparison of the proportion of subjects with plasma HIV-1 RNA levels <50 (and <400) copies/mL through week 48, using the time to loss of virologic response (TLOVR) algorithm. The TLOVR algorithm was employed for the identification of responders for the primary end point analysis, namely, the plasma HIV-1 RNA AAUCMB of FDC versus SE components of the randomized treatment. In this algorithm, a virologic response is not counted as a virologic success or a VF until it is confirmed. A responder was defined as a patient who achieved confirmed plasma HIV-1 RNA levels at or below a predefined level (<50 and <400 copies/mL) and had not yet lost the virologic response by study week 48. Nonresponders at week 48 were subdivided into VF and non-VF groups based on outcomes determined by the TLOVR algorithm. For subjects with plasma HIV-1 RNA below the limit of detection for the assay (<50 copies/mL or 1.69 log10 copies/mL), plasma HIV-1 RNA values were imputed to 49 copies/mL or 1.69 log10 copies/mL for all subsequent efficacy analyses.
The median difference (delta) in HIV-1 RNA AAUCMB between the 2 arms was constructed using Hodges-Lehmann point estimate as the median of all the n1 × n2 ordered differences, where n1 and n2 are the numbers of subjects in the 2 treatment arms. Therefore, delta is not simply equal to the difference in medians as calculated for each arm separately.
Immunologic efficacy was measured as simple changes in CD4 cell count.
The safety population included all subjects exposed to study drugs. Any misrandomization was summarized according to the drugs actually received rather than by the randomization schedule.
To evaluate adherence, the number of pills consumed was calculated by subtracting the number of pills returned from the number of pills supplied. At study visits, where the subject did not return any pills, the number of pills returned was recorded as "0" only if the subject returned the original packaging; otherwise, the value was considered missing and excluded from the analysis. Adherence was calculated by dividing the number of pills consumed by the number of pills that should have been consumed.
The primary adherence comparison of interest was the proportion of subjects who were ≥95% adherent to FDC versus the proportion that were ≥95% adherent to SE. Treatment groups were compared based on adherence over the entire randomized treatment phase and based on the last pill count while on randomized treatment (LTORT) using the Cochran Mantel-Haenszel test, with stratification by baseline plasma HIV-1 RNA and genotype. An exploratory analysis compared the treatment groups in terms of the proportion of subjects who were ≥95% adherent to both FDC or SE and TDF, both at LTORT, and over the entire randomized treatment phase.
A total of 186 subjects were randomized to either the FDC group (n = 95) or the SE group (n = 91). Of the subjects randomized, 4 did not initiate treatment (1 in the FDC group; 3 in the SE group). In total, 25% (45/182) of the subjects in the ITT-exposed population discontinued the study. The proportion of subjects discontinuing study drug was similar in the FDC and the SE groups (Table 1).
Demographic and Baseline Characteristics
Demographic characteristics and results of assessment of baseline characteristics for the ITT-exposed population are summarized in Table 2. Overall, the treatment groups were well matched with regard to the demographic characteristics. Most subjects were male (76%) and white (66%). The 2 treatment groups were generally comparable with regard to the baseline characteristics. There was, however, a statistically significant difference between the 2 treatment groups in the median plasma HIV-1 RNA levels at baseline (FDC group = 3.92 log10 copies/mL; SE group = 4.22 log10 copies/mL; P = 0.017), which was not observed at screening.
Previous ART and Fourth ART at Baseline
All subjects were taking highly active ART before entry into the study (Table 3). The most commonly prescribed NRTIs before the study start were 3TC (98%), composed of 3TC, Combivir (3TC/ZDV), and Trizivir (ABC/3TC/ZDV); ZDV (63%), composed of ZDV, Combivir (3TC/ZDV), and Trizivir (ABC/3TC/ZDV); and d4T (55%). ABC-containing regimens (including Trizivir) were used before study entry by 13% and 19% of subjects in the FDC and SE groups, respectively.
Fifty-six percent of subjects took PI as their fourth drug during the course of the study. Overall, the most commonly used fourth drug was lopinavir/ritonavir (FDC, 35%; SE, 42%) or efavirenz (FDC, 35%; SE, 26%). Of subjects taking PIs, the majority continued taking PI as their fourth drug throughout the study period (FDC group, 51%; SE group, 52%). Only 1 subject in the SE group switched from PI to NNRTI, and 7 subjects switched to a different PI (2 in the FDC group; 5 in the SE group). More subjects initiated NNRTI therapy in the FDC group (45%) than in the SE group (35%).
Overall, baseline NRTI mutations were balanced between the 2 treatment groups. The most common baseline NRTI resistance-associated mutation was at reverse transcription residue 184 (ITT-exposed population: 124/182 subjects, 68% with M184V and/or I mutation; VF population: 22/31 subjects, 71% with M184V and/or I mutation). TAMs were present in significant numbers in the subjects of the ITT-exposed population (132 TAMs in 72 of 182 subjects; 40%) but were fewer in the subjects of the VF population (12 TAMs in 6 of 31 subjects; 19%). The findings suggest that subjects with baseline TAMs may not be particularly susceptible to VF. In addition, there were differences in the distributions of individual TAMs between treatment groups, with more M41L and T215Y/F mutations in the FDC group and more of the K70R mutation in the SE group. Finally, subjects treated with PI tended to have more TAMs at baseline than those treated with NNRTI (total baseline TAMs: NNRTI subjects, n = 35; PI subjects, n = 92). For the most part, those subjects treated with NNRTI were assigned to this therapy without the presence of a genotype predictive of NNRTI resistance (NNRTI treated and susceptible: FDC = 37/42, 88%; SE = 30/31, 97%). In the PI-treated subjects, there was a higher proportion of subjects with primary PI mutations in the SE arm (12 of 51 subjects taking PI, 50%) than in the FDC arm (12 of 51 subjects taking PI).
Table 4 presents median plasma HIV-1 RNA AAUCMB data at week 48 for the ITT-exposed population (observed data), stratified by baseline viral load and the presence or the absence of the M184V mutation at baseline. At week 48, the median plasma HIV-1 RNA AAUCMB was −1.65 and −1.83 log10 copies/mL for the FDC and SE groups, respectively. The stratified median difference between the 2 treatment groups at week 48 was 0.13 log10 copies/mL (95% CI: −0.13, 0.38). Because the 95% confidence limit was below the predefined noninferiority margin (0.4 log10 copies/mL), the noninferiority of the FDC group compared with the SE group over a 48-week treatment period was confirmed.
Overall, the median number of days contributing to AUC during the 48-week treatment period was similar in the 2 treatment groups (FDC group: 360 days, range 10-378; SE group, 362 days, range 22-378).
Plasma HIV-1 RNA AAUCMB was summarized for the ITT-exposed population (observed data) by gender, age, race, country, and fourth drug (data not shown). No statistically significant (P ≥ 0.4194) differences were found between the treatment groups in relation to any of the subgroups analyzed.
Median plasma HIV-1 RNA values are presented for the ITT-exposed population (observed data) in Figure 1. Five subjects were noted as having prematurely discontinued from the study at their week 48 visit; however, these subjects did have week 48 efficacy data available (plasma HIV-1 RNA) that was included in Figure 1.
The slope of viral decay was similar between the 2 treatment groups, with reductions in median plasma HIV-1 RNA at week 48 of greater than 1.8 log10 copies/mL from baseline in both treatment groups.
During the 48-week treatment period, a similar proportion of subjects maintained viral suppression in the FDC group relative to the SE group, based on the TLOVR algorithm. At week 48, the proportion with viral load <50 copies/mL was 50% in the FDC group compared with 47% in the SE group (Fig. 2).
In the study population stratified by baseline viral load and presence or absence of M184V/I, the proportions of subjects in the FDC and SE groups with viral loads <50 and <400 copies/mL at week 48 were similar. The proportion of subjects defined as VFs was similar between the groups (FDC group, 16%; SE group, 18%).
At baseline the median CD4 cell counts were 304 cells/μL in the FDC group and 309 cells/μL in the SE group. During the 48-week treatment period, both treatment groups were associated with nominal increases in median CD4 cell counts from baseline. At week 48, the median change from baseline in CD4 cell counts was +47.5 cells/μL (25th and 75th percentiles, −18 and 117) in the FDC group and +95.0 cells/μL (25th and 75th percentiles, 7 and 169) in the SE group.
The incidence of HIV-1-associated conditions during the 48-week treatment period was low and comparable between the treatment groups (2% in each group). Furthermore, no subjects had progression of their HIV disease state during the study period.
Incidences of drug-related AEs by body system were generally comparable between treatment groups (FDC group, 48%; SE group, 46%; Table 5). In both treatment groups, the body system with the highest incidence of drug-related AEs was gastrointestinal disorders (FDC group, 26%; SE group, 26%). Serious adverse events (SAEs) were reported in 16% (FDC) and 9% (SE) of subjects during the study; none of the SAEs reported were fatal. This difference was mainly driven by reports of drug hypersensitivity, which was reported in 9% of subjects in the FDC group and 4% in the SE group. The incidences of specific treatment-emergent grades 3 and 4 clinical chemistry and hematology abnormalities were low and generally comparable between treatment groups.
The incidence of all AEs and laboratory abnormalities were significantly lower during the second 24-week phase of the study in both treatment groups, especially severe AEs, drug-related AEs, and AEs leading to treatment terminations (data not shown). The safety profiles of the second 24-week phase were comparable between the 2 treatment groups.
Most VFs defined with confirmed viral load >400 copies/mL were successfully analyzed at failure by viral genotype and phenotype (n = 29/31). The K65R mutation was the most commonly selected mutation (FDC, n = 4; SE, n = 3). It did not occur in the presence of TAMs but was positively associated with the M184V/I mutation (7/7) and with nevirapine use (5/7). The L74V mutation was selected in 1 subject per arm and the Y115F mutation was selected for in 3 subjects (FDC, n = 2; SE, n = 1). The selection of the M184V/I mutation was low, probably due to the high incidence of this mutation at baseline. Phenotype was generally predictable from genotype, although in some instances partial deselection of the M184V/I mutation resulted in resensitization to 3TC.
The coprimary adherence analyses were comparison of treatment groups at LTORT and comparison of groups across all time points in the randomized treatment phase. In the LTORT analysis, 67% (45/67) of patients in the FDC group were ≥95% adherent to ABC + 3TC compared with 53% (39/73) of patients in the SE group. Over the entire randomized treatment phase, 59% (49/83) of patients in the FDC group were ≥95% adherent to ABC + 3TC compared with 53% (42/79) of patients in the SE group. The differences between treatment groups for adherence to the ABC and 3TC portion of the regimens were not statistically significant (at LTORT P = 0.104; over randomized treatment phase, P = 0.417). Over the entire randomized treatment phase, the proportions of subjects who achieved ≥95% overall adherence to ABC + 3TC + TDF were 65% (44/68) versus 48% (35/73) at LTORT and 54% (46/85) versus 41% (33/80) in the FDC and SE groups, respectively.
In ART-naive subjects, ABC + 3TC has been successfully used as an NRTI backbone in a variety of regimens in both QD and BID dosing schedules.24-29 In 2 pilot studies, the elimination half-life of intracellular carbovir triphosphate (CBV-TP; the active moiety of ABC) was >12 hours, and inhibitory concentrations were maintained over 24 hours with either 300 mg BID or 600 mg QD dosing.30,31 Additionally, data from a clinical pharmacology study demonstrated a prolonged (21.64 hours) intracellular half-life of CBV-TP, which supports ABC 600 mg QD dosing.32 The bioequivalence analysis also indicated that ABC/3TC FDC QD was similar to ABC BID + 3TC BID based on AUC and Cmax.33 Therefore, ABC has received approval for QD dosing in the United States, the European Union, and other regions recently. The study is one of the first trials of ABC + 3TC in HIV therapy-experienced patients. The efficacy results of this study demonstrated that over 48 weeks of treatment, the FDC group was noninferior to the SE group with respect to plasma HIV-1 RNA AAUCMB, the primary end point of the study. AAUCMB provides a useful measure of antiviral activity in therapy-experienced subjects with VF,23 as it allows measurements at multiple time points to contribute to the overall measurement of efficacy. The end point is less sensitive to missing data, and this has a lower variability compared with absolute change in plasma HIV-1 RNA. However, its value as an end point is dependent on treatment groups being comparable with respect to baseline plasma HIV-1 RNA levels. Although AAUCMB was the primary end point in this trial, secondary end points included a comparison of the proportions of subjects with plasma HIV-1 RNA <50 and <400 copies/mL, as these are important surrogate markers of long-term efficacy. In the analyses of these secondary parameters of efficacy, there were comparable proportions of subjects with plasma HIV-1 RNA values <50 copies/mL in the FDC group compared with the SE group (50% vs. 47%) based on the TLOVR algorithm. Similar results were also observed in the proportions of subjects with plasma HIV-1 RNA values <400 copies/mL. Overall, these results supplement and are consistent with the observations based on AAUCMB. Subsequent to the enrollment of this study, frequent early failure leading to treatment termination was documented in several clinical trials including studies in ART-naive HIV-1-infected subjects treated with ABC + 3TC + TDF once daily34-36 and ddI + 3TC + TDF.37 These cases were characterized by the presence of M184V or M184I in nearly all instances, with the selection of K65R in 50%-82% of genotyped viruses. Although ABC, 3TC, and TDF have been used as part of the treatment regimens in this study, it is reassuring that similar high failure rates were not observed. This suggests that the fourth drug (new PI or NNRTI) had a modulating effect on efficacy with this triple NRTI regimen. More detailed analyses of the virologic data of this study are ongoing. Analyses of baseline genotypes observed no gross differences of numbers in subjects with NRTI resistance-associated mutations between the 2 treatment groups. However, several discrete differences within and between the groups may underlie the variable virologic response observed within this study. There were markedly more TAMs present in subjects treated with PIs across both treatment groups, and it is not clear if the presence of these TAMs was associated with the fewer VFs observed among the subjects treated with PIs. In addition, small differences in specific baseline viral mutations suggest a slight bias against the FDC group, where there were more subjects with resistance to 3TC, more subjects with M41L and T215Y/F mutations, and more subjects treated with NNRTI. This might have been offset to some extent by the slightly higher mean plasma HIV-1 RNA concentration in the SE group, and although the intent of the stratified randomization by study entry plasma HIV-1 RNA was to ensure an equal distribution between the groups, this may not have occurred. More detailed analyses of the virologic data from the treatment phase of the study are ongoing Both treatment groups were associated with small increases in CD4 cell counts from baseline, which was expected in this subject population. The levels of CD4 cell count increases over 48 weeks were not significantly different between the 2 treatment groups. The clinical relevance of the small difference between the 2 treatment groups is therefore unknown. In the primary adherence analysis, the proportion of subjects who were at least 95% adherent to the ABC and 3TC portion of the regimen was numerically higher in the FDC group than in the SE group (59% vs. 53% based on average adherence over the first 48 weeks; 67% vs. 53% based on LTORT). Although these differences were not statistically significant (P = 0.417 and 0.104, respectively), the study was not powered to detect adherence differences. It is notable that both methods of analyzing adherence indicate a trend favoring the FDC group. Moreover, the adherence benefit of an FDC product is likely to be more pronounced in the real world, where it not only reduces pill burden but also reduces the number of prescriptions to be filled. The real-world adherence benefits of FDC products are suggested by 2 observational database studies comparing another FDC product containing 3TC and ZDV (Combivir, GlaxoSmithKline) to its components. In these studies, patients receiving the FDC were 2-3 times more likely to achieve optimal adherence than patients given the component medications.38,39 SAEs were reported in 16% of subjects in the FDC group and 9% in the SE group. This difference was mainly driven by drug hypersensitivity. The rate of ABC HSR was 9% in the FDC group and 4% in the SE group. However, the significance of the observed differences was difficult to account for and most likely related to the relatively small size of the overall treatment population. Recent label changes for ABC-containing products are reflective of the rates observed in this study. In addition, hypersensitivity was reported as an SAE regardless of whether the event met the regulatory definition. The presentation of reported hypersensitivity did not change when ABC was administered QD or BID, and most cases were reported within 6 weeks of initiating ABC. No subject required hospitalization because of hypersensitivity. It is possible that overlapping toxicities associated with the use of NNRTI as the fourth drug may have contributed to a slightly higher proportion of subjects in the FDC group reporting hypersensitivity. The low absolute number of subjects reporting hypersensitivity makes it difficult to draw conclusions about the difference in reporting rate in each study group. Indeed, there were only 4 additional cases in the FDC group, and therefore a chance difference is likely.40 It has already been established that the safety and tolerability of the FDC regimen is comparable with the SE regimen during the first 24-week treatment period of this study.41 The significantly lower incidences of total AEs and laboratory abnormalities during the second 24-week period suggest that FDC-containing regimens are likely to have favorable safety profiles in the long-term treatment of HIV-1-infected patients, as has previously been demonstrated for SE-containing regimens. In conclusion, the results of this study demonstrated that the FDC arm had noninferior efficacy over 48 weeks to the SE arm in ART-experienced subjects with prior VF. The 2 regimens were generally well tolerated with similar safety profiles. The once-daily ABC/3TC FDC is a simple and effective NRTI backbone for both ART-naive and ART-experienced patients.
The authors thank the CAL30001 study participants and acknowledge the CAL30001 study investigators (Drs Bisher Akil, Daniel Alvarez, Keikawus Arasteh, Juan Bandres, Jean-Francois Bergmann, Michel Boissonnault, Maria Branco, Giampiero Carosi, Alexandre Carvalho, Alfonso del Arco, Rafael Rubio, Jean-Francois Delfraissy, Edwin DeJesus, Antonio Diniz, Roberto Esposito, Vicente Estrada, Brian Gazzard, Jose Giron, Eliot Godofsky, Kevin Gough, Stephen Green, Felix Gutierrez, Jose Hernandez, Hans Jaeger, Margaret Johnson, Patrice Junod, Daniel Kaul, Donald Kilby, Birger Kuhlmann, Jean-Claude Legrand, Josep Mallolas, Jean-Michel Livrozet, Brobson Lutz, Antonio Melico-Silvestre, Mauro Moroni, Cheryl Newman, David Parks, Enric Pedrol, Jose Maria Peña, Federico Pulido, Anita Rachlis, Esteban Ribera, Reinhold Schmidt, Robert Schwartz, Peter Shalit, Laura Sighinolfi, Melanie Thompson, Julia Torres, Jose Vera, Sharon Walmsley, Jonathan Weber, Winkler Weinberg, and Mary Weinert). We also acknowledge the assistance of the CAL30001 Study Conduct Team.
1. Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Panel report; 23 March 2004.
2. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA
3. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis
4. D' Aquila RT, Schapiro JM, Brun-Vezinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med
5. Iverson AK, Shafer RW, Wehrly K, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol
6. Larder BA, Bloor S, Kemp SD, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcription confer multinucleoside analogue resistance. Antimicrob Agents Chemother
7. Lanier ER, Ait-Khaled M, Scott J, et al. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring virus with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir Ther
8. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis
. 2004;189(5): 837-846.
9. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther
10. Miller MD, Margot N, Coakley D, et al. Anti-HIV responses and development of RT mutations in antiretroviral-experienced patients adding tenofovir DF (TDF) therapy: baseline and week 24 genotypic analyses of study 907. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago, IL.
11. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther
12. StClair MH, Martin JL, Tudor-William G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science
13. Miller V, Ait-Khaled M, Stone C, et al. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS
14. Srinivas RV, Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis (isopropyloxymethylcarbonyl) PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother
. 1998;42: 1484-1487.
15. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science
16. Gotte M, Arion D, Parniak MA, et al. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol
17. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother
18. Harrigan PR, Stone C, Griffin P, et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis
19. Lanier ER, Irlbeck D, Ross L, et al. Prediction of NRTI options by linking reverse transcriptase genotype to phenotypic breakpoints. Presented at: 10th Conference on Retroviruses and opportunistic infection; 2003; Boston, MA.
20. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep
21. Division of AIDS. Division of AIDS table for grading the severity of adult adverse experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases; 1992. Available at: http://rcc.tech-res-intl.com
22. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS
23. Food and Drug Administration. Guidance for Industry: Antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval; October 2002.
24. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine versus indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults. JAMA
25. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis
26. Moyle G, DeJesus E, Cahn P, et al. Abacavir 600 mg once daily versus 300 mg twice-daily combined with lamivudine in combination with efavirenz (EFV) QD is well-tolerated and effective in the treatment of antiretroviral therapy (ART) naïve adults with HIV-1 infection (ZODIAC Study: CNA30021). J Acquir Immune Defic Syndr
27. Bartlett JA, Johnson J, Herrera G, et al. Initial therapy with abacavir + lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. Presented at: 15th International AIDS Conference; 2004; Bangkok, Thailand.
28. Gallant J, Rodriguez AE, Weinberg W et al. Efficacy of once-daily abacavir/lamivudine fixed-dose combination (ABC/3TC FDC) + efavirenz and subsequent treatment of tenofovir + ABC/3TC nonresponders: ESS30009 planned 24-week analysis. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC.
29. Gathe JC, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1 infected patients. AIDS
30. Kewn S, Maher B, Hoggard PG, et al. The pharmacokinetics of abacavir phosphorylation in peripheral blood mononuclear cells from HIV-positive subjects. Presented at: 5th International Congress on Drug Therapy in HIV Infection; 2000; Glasgow, Scotland.
31. Harris M, Back D, Kewn S, et al. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS
32. Piliero P, Shachoy-Clark AD, Para M, et al. A Study Examining the Pharmacokinetics of Abacavir and the Intracellular Carbovir Triphosphate (CNA10905). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.
33. Baker K, Lou Y, Yuen G, et al. The bioequivalence and effect of food on a new once-a-day fixed-dose combination tablet of abacavir (ABC) and lamivudine (3TC). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington DC.
34. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in treatment naive HIV-infected patients. Antivir Ther
. 2003;8(suppl 1):S195. (Abstract 43).
35. Gallant JE, Rodriguez A, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomised trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.
36. Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine and tenofovir: The TONUS Study. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA.
37. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir DF. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA.
38. Jordan J, Delea T, Sherrill B et al. Impact of fixed dose combination zidovudine/lamivudine on adherence to antiretroviral therapy: a retrospective claims-based cohort study. Presented at: 6th International Congress on Drug Therapy in HIV Infection; 2002; Glasgow, Scotland.
39. Legorreta A, Yu A, Chernicoff H, et al. Adherence to combined lamivudine + zidovudine versus individual components: a community-based retrospective Medicaid claims analysis. AIDS Care
40. Cutrell A, Hernandez J, Fleming J, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother
41. Clumeck N, LaMarca A, Fu K, et al. Safety and efficacy of a once daily (QD) fixed-dose combination (FDC) of ABC/3TC [FDC arm] versus ABC twice daily (BID) and 3TC QD as separate entities [SE arm] in ART-Experienced HIV-1 infected patients. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC.